Principal Financial Group Inc. Makes New Investment in AngioDynamics, Inc. (NASDAQ:ANGO)

Principal Financial Group Inc. purchased a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 95,961 shares of the medical instruments supplier’s stock, valued at approximately $879,000. Principal Financial Group Inc. owned 0.24% of AngioDynamics as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in shares of AngioDynamics by 1.7% during the 4th quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier’s stock valued at $554,000 after acquiring an additional 1,021 shares in the last quarter. White Pine Capital LLC lifted its position in shares of AngioDynamics by 189.6% in the 4th quarter. White Pine Capital LLC now owns 64,033 shares of the medical instruments supplier’s stock worth $587,000 after buying an additional 41,925 shares during the last quarter. R Squared Ltd bought a new position in shares of AngioDynamics during the fourth quarter valued at approximately $49,000. SG Americas Securities LLC lifted its stake in AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 2,832 shares during the last quarter. Finally, Moody National Bank Trust Division grew its position in AngioDynamics by 70.2% in the 4th quarter. Moody National Bank Trust Division now owns 55,780 shares of the medical instruments supplier’s stock worth $511,000 after purchasing an additional 23,003 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Up 0.5 %

Shares of NASDAQ ANGO opened at $9.41 on Friday. The stock’s fifty day simple moving average is $10.83 and its 200 day simple moving average is $8.56. The stock has a market capitalization of $380.79 million, a price-to-earnings ratio of -1.67 and a beta of 0.60. AngioDynamics, Inc. has a 52-week low of $5.26 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same quarter last year, the business posted ($0.05) EPS. AngioDynamics’s revenue was down .1% on a year-over-year basis. As a group, analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright raised their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

Insider Activity at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.40% of the stock is owned by insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.